Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981345 | 0.92 | MEN1 (0.44) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850212 | 0.77 | MEN1 (0.58) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850240 | 0.76 | MEN1 (0.46) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850333 | 0.75 | MEN1 (0.50) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850326 | 0.74 | MEN1 (0.61) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5851863 | 0.73 | MEN1 (0.48) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850349 | 0.73 | MEN1 (0.53) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5852119 | 0.73 | MEN1 (0.56) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850225 | 0.71 | MAPT (0.51) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL5850480 | 0.71 | LMNA (0.51) | LMNAMEN1MAPTKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056348-B2 | 5-aryl-1,3,3-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibers | WELLA AG (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20030213071-A1 | 5-Aryl-1.3.3.-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibres | Wella GmbH (DE) | 2003-11-20 | — | — | US | disclosed |
| EP-1280773-A1 | 5-ARYL-1.3.3.-TRIMETHYL-2-METHYLENE-INDOLINE DERIVATIVES AND SALTS THEREOF, METHODS FOR THE PRODUCTION AND USE OF SAID COMPOUNDS FOR THE TEMPORARY COLORATION OF FIBRES | Wella Aktiengesellschaft (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2002085854-A1 | 5-ARYL-1.3.3.-TRIMETHYL-2-METHYLENE-INDOLINE DERIVATIVES AND SALTS THEREOF, METHODS FOR THE PRODUCTION AND USE OF SAID COMPOUNDS FOR THE TEMPORARY COLORATION OF FIBRES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030213071-A1 | 5-Aryl-1.3.3.-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibres | INMT, KRT18, IPO5 | LMNA 27/4885MEN1 1991/4885MAPT 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.